Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevirumab (MSL-109) for CMV Retinitis in AIDS
NCT00001061Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sevirumab in cytomegalovirus retinitis (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Time to progression of CMV retinitis. Status: completed.
02
Drugs
sevirumab
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00001061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001061.